PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
40614182,Safety and immunogenicity of intranasal parainfluenza virus type 5 (PIV5)-vectored COVID-19 vaccine in adults and teens in an open-label phase 1 trial.,2025-Jul-04,Hong Jin; Kristeene Knopp; Henry Radziewicz; Marinka Tellier; Zhuo Li; Maria Cristina Gingerich; Samuel Wu; Biao He,N/A,N/A
40613499,A pan-beta-coronavirus vaccine bearing conserved and asymptomatic B- and T-cell epitopes protects against highly pathogenic Delta and highly transmissible Omicron SARS-CoV-2 variants.,2025-Dec,Hawa Vahed; Jeffrey B Ulmer; Daniel Gil; Lbachir BenMohamed,N/A,N/A
40609106,Correspondence on incidence and factors associated with adverse reactions after the first dose of COVID-19 vaccine.,2025,Amnuay Kleebayoon,N/A,N/A
40607738,Rebuilding vaccine confidence in Latin America and the Caribbean: strategies for the post-pandemic era.,2025-Dec,Silvia Enrique,N/A,N/A
